Dave Rosa: Yes, so I haven’t participated in discussions about how they plan on using it when Zimmer has held the meetings. I mean, we’ve definitely been able to attend the sessions where these doctors have been, but the feedback was – that was really requested was on the electrode itself and the feel of it, the tactile feel of it, the features of it. There was definitely no discussion about using this in just select cases. There would be no reason to use any other electrode, over our electrode. And at least none of that ever came up in any of the discussions that I participated in or had ever heard of. So this is intended to be a replacement for all of the sEEG electrodes that are being used today.
Alex Nowak: Okay, that’s great. And then just two more questions that the first one is just any update around the pulse generator that you plan on using for the product you use electrode? I know you’ve talked about some potential some strategic partnerships there in the past. Is there any update? And then just the second question was with regards to capital, needs for capital. Just how to think about that? And should we also think about there could be, whether it be something similar to Zimmer where you have non-dilutive capital come and through a partnership?
Dave Rosa: Yes, so I’ll answer the capital part first. So yes, I mean at some point, during the course of 2023, we’re going to need capital, but regarding the ablation technology that I talked about. We’ll just say there’s been strategic interest in that technology. So, the goal here is to explore non-dilutive capital first. And those discussions are happening now that’s always going to be the first option. And if not, obviously, there’s other ways of generating capital. We have an ATM in place. We can always do a capital raise as well. But our efforts right now are really focused on non-dilutive capital, because of the interest in the ablation system that we have. And I’m sorry, but I forgot what your first question was.
Alex Nowak: That’s okay. Just any update around the pulse generator for chronic use?
Dave Rosa: No I mean, the same options that we had before, we still have. So there’s really nothing new with that. What we are working on in addition to the electrode is now we have to start designing the connectors so that the electrode can communicate with the system that we’re intending to use. But nothing further on negotiations or anything like that.
Alex Nowak: Okay, understood. Appreciate the update. Thank you.
Dave Rosa: Thank you, Alex.
Operator: Our next question comes from the line of Ben Haynor with Alliance Global Partners. Please proceed with your question.
Ben Haynor: Good afternoon, guys. Thanks for taking the questions. Just wanted to check one thing, did you say Zimmer is launching – when they are launching by the end of this calendar quarter was it the end of this calendar year?
Dave Rosa: It will not be this calendar year. It would be calendar quarter.
Ben Haynor: Okay. I thought I heard that right, okay just making sure.
Dave Rosa: Don’t scare me.
Ben Haynor: Okay. So that – maybe I misheard it, I apologize. And then, can you characterize kind of the product forecast on the sEEG electrode that you’ve got and any implications that has for manufacturing on your end?
Dave Rosa: Yes, so I mean, we have forecast that Zimmer has given us over the next 12 months. We’re actually manufacturing right now as I said in my comments, units for the rest of the year. So I’m not sure in essence what you’re – if you’re wondering like what the impact is from a manufacturing capability is that where you’re going or is it something different?
